Insulet Stock News

Private Advisor Group LLC cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,700 shares of the medical instruments suppliers stock after selling 200 shares during the period. Private []

Insulet (NASDAQ:PODD)s stock had its buy rating restated by stock analysts at SVB Leerink in a report released on Tuesday, Price Targets.com reports. Several other brokerages have also weighed in on PODD. Canaccord Genuity increased their price objective on Insulet from $300.00 to $330.00 and gave the stock a buy rating in a research report []

SVB Leerink reiterated their buy rating on shares of Insulet (NASDAQ:PODD) in a research note issued to investors on Tuesday, PriceTargets.com reports. A number of other brokerages have also recently issued reports on PODD. Canaccord Genuity lifted their price objective on Insulet from $300.00 to $330.00 and gave the company a buy rating in a []

The conventional treatments for amblyopia include deflective correction, obstruction, and atropine penalization. Optimum refractive improvement alone can resolution in at least one-third of cases with crude anisometropic amblyopia and even some unprocessed strabismic amblyopia. All actions for amblyopia are based

The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on. SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of [] The post Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back appeared first on Drug Delivery Business .

This past Friday two events spooked the diabetes device world. The first was news that Abbott filed an IP lawsuit against Dexcom, the second Insulet announced the OmniPod 5 approval would not come before the end of 2021 more likely sometime in the first quarter The post These things happen appeared first on Diabetic Investor .

Equities research analysts expect Insulet Co. (NASDAQ:PODD) to post $0.31 earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Insulets earnings, with the highest EPS estimate coming in at $0.37 and the lowest estimate coming in at $0.23. Insulet reported earnings of ($0.26) per share in the []

Equities analysts forecast that Insulet Co. (NASDAQ:PODD) will report earnings per share (EPS) of $0.31 for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Insulets earnings. The highest EPS estimate is $0.37 and the lowest is $0.23. Insulet posted earnings of ($0.26) per share during the same quarter last year, []

LAS VEGAS , Dec. 1, 2021 /PRNewswire/ -- DelveInsight''s Insulin Delivery Devices Market Insights and Forecast report provides the current and forecast Insulin Delivery Devices Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Insulin Delivery Devices Market. Some of the salient features from the Insulin Delivery Devices Market report: As per DelveInsight analysis, in terms of revenue share, APAC is predicted to register the fastest growth in the Insulin Delivery Devices market because of the high prevalence of diabetes. Major pharma players working proactively in the Insulin Delivery Devices Market include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean ( Hangzhou ) Medical Technology Co Ltd, Owen Mumford , SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others.

Eastern Bank lifted its stake in Insulet Co. (NASDAQ:PODD) by 76.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,469 shares of the medical instruments suppliers stock after acquiring an additional 5,838 shares during the quarter. Eastern Banks holdings in Insulet were worth $3,828,000 []

NuWave Investment Management LLC trimmed its position in shares of Insulet Co. (NASDAQ:PODD) by 42.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 262 shares of the medical instruments suppliers stock after selling 195 shares during the quarter. NuWave Investment Management LLCs holdings in Insulet were worth $74,000 as of its most recent []

Exchange Traded Concepts LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 0.4% during the third quarter, Holdings Channel.com reports. The fund owned 12,420 shares of the medical instruments suppliers stock after selling 50 shares during the period. Exchange Traded Concepts LLCs holdings in Insulet were worth $3,530,000 at the end of the []

Juncture Wealth Strategies LLC reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 78.4% during the third quarter, Holdings Channel reports. The institutional investor owned 760 shares of the medical instruments suppliers stock after selling 2,751 shares during the period. Juncture Wealth Strategies LLCs holdings in Insulet were worth $216,000 as of its most []